Astra Zeneca Phase 3 Trial for COVID-19

 

AstraZeneca (NYSE:AZN) is starting Phase 3 trials of its experimental coronavirus vaccine in the U.S., becoming the third company to start late-stage trials to prevent COVID-19. Trial centers across the nation are recruiting up to 30K adults aged 18 years or over. AstraZeneca’s vaccine, known as AZD1222, was developed in partnership with Oxford University and has the backing of the U.S. government. Rivals Moderna (NASDAQ:MRNA) and Pfizer (NYSE:PFE)/BioNTec (NASDAQ:BNTX) already have Phase 3 trials under way, also with federal funding.

 

Walmart Partners with Microsoft on TikTok Bid.

 

Warren Buffets Top Holdings : Apple Stock is 44% of His Portfolio

 

 

 

Comments


CWEB.com is not registered as an investment adviser with the U.S. Securities and Exchange Commission. Rather, CWEB.com relies upon the “publisher’s exclusion” from the definition of investment adviser as provided under Section 202(a)(11) of the Investment Advisers Act of 1940 and corresponding state securities laws.

Full Disclaimer

%d bloggers like this: